Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy.

Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, Lafon ME, Boyer B, Alain S, Garrigue I, Merville P.

Am J Transplant. 2012 Jan;12(1):202-9. doi: 10.1111/j.1600-6143.2011.03766.x. Epub 2011 Oct 3.

PMID:
21967659
[PubMed - indexed for MEDLINE]
Free Article
2.

Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.

van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.

Transplantation. 2010 Feb 15;89(3):320-6. doi: 10.1097/TP.0b013e3181bc0301.

PMID:
20145523
[PubMed - indexed for MEDLINE]
3.

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.

Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group.

Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.

PMID:
22094954
[PubMed - indexed for MEDLINE]
4.

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.

Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC.

Am J Transplant. 2006 Sep;6(9):2134-43. Epub 2006 Jun 19.

PMID:
16780548
[PubMed - indexed for MEDLINE]
Free Article
5.

Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.

Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.

Transplantation. 2011 Jul 27;92(2):217-23. doi: 10.1097/TP.0b013e31821fad25.

PMID:
21685829
[PubMed - indexed for MEDLINE]
6.

Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.

Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V.

Am J Transplant. 2008 Jan;8(1):69-77. Epub 2007 Oct 31.

PMID:
17973956
[PubMed - indexed for MEDLINE]
Free Article
7.

Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.

Boutolleau D, Deback C, Bressollette-Bodin C, Varnous S, Dhedin N, Barrou B, Vernant JP, Gandjbakhch I, Imbert-Marcille BM, Agut H.

Antiviral Res. 2009 Feb;81(2):174-9. doi: 10.1016/j.antiviral.2008.11.003. Epub 2008 Dec 6.

PMID:
19063923
[PubMed - indexed for MEDLINE]
8.

Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.

Iwasenko JM, Scott GM, Naing Z, Glanville AR, Rawlinson WD.

Transpl Infect Dis. 2011 Apr;13(2):145-53. doi: 10.1111/j.1399-3062.2010.00584.x. Epub 2010 Nov 10.

PMID:
21070537
[PubMed - indexed for MEDLINE]
9.

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.

Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M.

J Infect Dis. 2002 Jan 1;185(1):20-7. Epub 2001 Dec 14.

PMID:
11756977
[PubMed - indexed for MEDLINE]
Free Article
10.

Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.

Martin M, Goyette N, Ives J, Boivin G.

J Clin Virol. 2010 Apr;47(4):321-4. doi: 10.1016/j.jcv.2010.01.009. Epub 2010 Feb 6.

PMID:
20138805
[PubMed - indexed for MEDLINE]
11.

Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.

Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR.

Clin Transplant. 2008 Mar-Apr;22(2):162-70. doi: 10.1111/j.1399-0012.2007.00761.x.

PMID:
18339135
[PubMed - indexed for MEDLINE]
12.

Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.

Scott GM, Naing Z, Pavlovic J, Iwasenko JM, Angus P, Jones R, Rawlinson WD.

J Clin Virol. 2011 Aug;51(4):229-33. doi: 10.1016/j.jcv.2011.05.012. Epub 2011 Jun 8.

PMID:
21641274
[PubMed - indexed for MEDLINE]
13.

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.

Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV.

Transplantation. 2005 Jan 15;79(1):85-90.

PMID:
15714174
[PubMed - indexed for MEDLINE]
14.

Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.

Potena L, Grigioni F, Magnani G, Lazzarotto T, Musuraca AC, Ortolani P, Coccolo F, Fallani F, Russo A, Branzi A.

J Heart Lung Transplant. 2009 May;28(5):461-7. doi: 10.1016/j.healun.2009.02.009.

PMID:
19416774
[PubMed - indexed for MEDLINE]
15.

New developments in the management of cytomegalovirus infection after solid organ transplantation.

Eid AJ, Razonable RR.

Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000. Review.

PMID:
20481654
[PubMed - indexed for MEDLINE]
16.

Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.

Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV.

Liver Transpl. 2008 Feb;14(2):240-4. doi: 10.1002/lt.21362.

PMID:
18236404
[PubMed - indexed for MEDLINE]
Free Article
17.

[Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].

Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.

Rev Invest Clin. 2002 May-Jun;54(3):198-203. Spanish.

PMID:
12183888
[PubMed - indexed for MEDLINE]
18.

Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.

Transplant Proc. 2007 Sep;39(7):2228-30.

PMID:
17889146
[PubMed - indexed for MEDLINE]
19.

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.

Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A.

Antivir Ther. 2009;14(5):697-704.

PMID:
19704173
[PubMed - indexed for MEDLINE]
20.

Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.

Lisboa LF, Preiksaitis JK, Humar A, Kumar D.

Transplantation. 2011 Nov 15;92(9):1063-8. doi: 10.1097/TP.0b013e31822fa4b7.

PMID:
21878838
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk